---
title: "Oscar Health, Inc. (NYSE:OSCR) Receives Average Recommendation of \"Hold\" from Brokerages"
description: "Oscar Health, Inc. (NYSE:OSCR) has received a consensus rating of \"Hold\" from nine analysts. The average 12-month price target is $21.56. Recent ratings include UBS Group's \"neutral\" at $23.00, Bank o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/224674677.md"
published_at: "2025-01-12T09:37:25.000Z"
---

# Oscar Health, Inc. (NYSE:OSCR) Receives Average Recommendation of "Hold" from Brokerages

> Oscar Health, Inc. (NYSE:OSCR) has received a consensus rating of "Hold" from nine analysts. The average 12-month price target is $21.56. Recent ratings include UBS Group's "neutral" at $23.00, Bank of America's downgrade to "underperform" with a target of $13.50, and Jefferies' "underperform" at $12.00. The stock opened at $14.12, with a 52-week range of $9.70 to $23.79. Oscar Health reported a revenue of $2.42 billion for the last quarter, missing EPS estimates but showing a 68.3% year-over-year revenue increase. Insiders have recently increased their holdings significantly.

Shares of Oscar Health, Inc. (NYSE:OSCR - Get Free Report) have been given a consensus rating of "Hold" by the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $21.56.

A number of equities analysts have weighed in on the stock. UBS Group assumed coverage on shares of Oscar Health in a research note on Monday, October 7th. They set a "neutral" rating and a $23.00 price target on the stock. Bank of America cut Oscar Health from a "neutral" rating to an "underperform" rating and reduced their target price for the company from $21.00 to $13.50 in a report on Wednesday, November 6th. Finally, Jefferies Financial Group initiated coverage on Oscar Health in a research note on Tuesday, December 10th. They set an "underperform" rating and a $12.00 price target for the company.

**View Our Latest Report on OSCR**

## Oscar Health Stock Performance

Oscar Health stock opened at $14.12 on Friday. The stock has a fifty day moving average price of $15.10 and a 200 day moving average price of $16.89. Oscar Health has a 52 week low of $9.70 and a 52 week high of $23.79. The firm has a market capitalization of $3.49 billion, a P/E ratio of -235.29 and a beta of 1.70. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.26.

Oscar Health (NYSE:OSCR - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.02). Oscar Health had a net margin of 0.35% and a return on equity of 2.79%. The company had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.33 billion. During the same period in the prior year, the company earned ($0.29) EPS. The company's revenue was up 68.3% compared to the same quarter last year. Equities research analysts anticipate that Oscar Health will post -0.01 earnings per share for the current year.

## Insider Activity at Oscar Health

In other news, Vice Chairman Joshua Kushner acquired 276,040 shares of the business's stock in a transaction on Monday, November 11th. The shares were purchased at an average price of $13.58 per share, for a total transaction of $3,748,623.20. Following the completion of the purchase, the insider now directly owns 5,031,262 shares of the company's stock, valued at $68,324,537.96. This represents a 5.80 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thrive Partners Vii Growth Gp, bought 420,819 shares of the firm's stock in a transaction dated Tuesday, November 12th. The stock was purchased at an average price of $13.68 per share, with a total value of $5,756,803.92. Following the transaction, the director now owns 5,452,081 shares in the company, valued at approximately $74,584,468.08. This represents a 8.36 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 1,055,478 shares of company stock worth $14,432,852 and have sold 103,610 shares worth $1,847,519. Company insiders own 25.11% of the company's stock.

## Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of OSCR. Westfield Capital Management Co. LP acquired a new stake in Oscar Health during the third quarter worth about $27,452,000. JPMorgan Chase & Co. raised its position in shares of Oscar Health by 68.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,309,150 shares of the company's stock worth $48,977,000 after purchasing an additional 938,742 shares during the period. Renaissance Technologies LLC raised its position in shares of Oscar Health by 31.7% during the 2nd quarter. Renaissance Technologies LLC now owns 3,886,100 shares of the company's stock worth $61,478,000 after purchasing an additional 934,600 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Oscar Health in the 2nd quarter worth approximately $14,716,000. Finally, Soros Fund Management LLC acquired a new position in Oscar Health during the 3rd quarter valued at approximately $12,726,000. 75.70% of the stock is currently owned by institutional investors.

## Oscar Health Company Profile

(Get Free Report

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

## Recommended Stories

-   Five stocks we like better than Oscar Health
-   How to Choose Top Rated Stocks
-   3 Defense Stocks Gaining From Budget and Interest Rate Pressures
-   Where to Find Earnings Call Transcripts
-   3 Natural Gas Stocks Set to Thrive in This Winter's Freeze
-   Investing in Construction Stocks
-   Bullish on Athleisure? Here’s Why Lululemon Stock Shines

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Oscar Health Right Now?

Before you consider Oscar Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oscar Health wasn't on the list.

While Oscar Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [OSCR.US - Oscar Health](https://longbridge.com/en/quote/OSCR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Oscar Health｜10-K：2025 财年营收 117 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/275946059.md) |
| Oscar Health｜8-K：2025 财年 Q4 营收 28.05 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/275448384.md) |
| 尽管面临奥巴马医改的阻力，Oscar Health 的前景超过市场预期，股价上涨 | Oscar Health (OSCR) 的股价上涨，因为该公司提供的 2026 年收入展望超出市场共识，尽管面临来自奥巴马医保保费上涨的挑战。该公司报告了 2025 年第四季度每股 GAAP 亏损 1.24 美元，收入为 28 亿美元，低于 | [Link](https://longbridge.com/en/news/275503652.md) |
| Oscar Health 预计尽管在 2025 年会有亏损，但在 2026 年将实现增长 | Oscar Health 已获得 4.75 亿美元的循环信贷额度，以增强流动性并支持增长。尽管预计 2025 年收入将增加至 117 亿美元，但由于医疗成本高企，公司报告了 3.964 亿美元的运营亏损。Oscar 预计 2026 年收入将 | [Link](https://longbridge.com/en/news/275451700.md) |
| Oscar Health (OSCR) 预计将在周二发布季度财报 | Oscar Health（纽约证券交易所代码：OSCR）将于 2026 年 2 月 10 日发布 2025 年第四季度财报，分析师预测每股亏损为 0.84 美元，收入为 31.234 亿美元。该公司此前报告 2025 年第三季度每股亏损 0 | [Link](https://longbridge.com/en/news/274608803.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
